Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination
Abstract
Human papillomaviruses (HPV) are the most common sexually transmitted pathogens worldwide, leading to infections with a wide range of clinical manifestations: from benign conditions to different types of cancer in women and men as well. Cervical cancer is highly correlated with persistent high-risk-HPV (HR-HPV) infection, which is the key factor in emergence of 99.99% of cervical cancer cases. The most effective way to prevent HPV-related cancers is vaccination. There are three available prophylactic HPV vaccines: bivalent, quadrivalent and nonavalent. The nonavalent vaccine is gradually replacing other HPV vaccines in most countries and can be given from year 9, but it is commonly routinely implemented at the age of 11 to 12. The World Health Organization has recognised cervical cancer as a global threat and has announced the so-called 90-70-90 strategy to reduce and even eliminate cervical cancer. This strategy implies that 90% of girls should be vaccinated by the age of 15, 70% of women should be screened for cervical cancer, and 90% of women diagnosed with cervical disease should receive adequate treatment. Although different treatment options are available: surgery, radiation therapy, chemotherapy, and advanced target therapy using monoclonal antibodies, great efforts are needed to achieve the goals set by the World Health Organization to eliminate cervical cancer.
References
Bishop B, Dasgupta J, Chen XS. Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly. Virol J. 2007;4:3.
Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020;8(1):28-37.
Seyoum A, Seyoum B, Gure, T, Alemu A, Alemayehu DH, Alemu A, et al. High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia. Sci Rep. 2024;14:958.
Rosalik K, Tarney C, Han J. Human Papilloma Virus Vaccination. Viruses. 2021;13(6):1091.
Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80-5.
Human papilloma virus and cancer [Internet]. World Health Organization; 2023 Aug 23 [cited 2023 Dec 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer.
HPV and cancer [Internet]. National Cancer Institute [cited 2023 Dec 23]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer.
Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, et al. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front Cell Infect Microbiol. 2022;12:909223.
eClinicalMedicine. Global strategy to eliminate cervical cancer as a public health problem: are we on track? EClinicalMedicine. 2023;55:101842.
HPV Centre [Internet]. [cited 2023 Dec 23]. Available from: https://hpvcentre.net/statistics/.
Global Cancer Observatory [Internet]. [cited 2024 Jan 15]. Available from: https://gco.iarc.fr.
Boon SS, Luk HY, Xiao C, Chen Z, Chan PKS. Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer. Cancers (Basel). 2022;14(12):2913.
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137. Erratum in: MMWR Recomm Rep. 2015;64(33):924.
Tasic D, Lazarevic I, Knezevic A, Tasic L, Pikula A, Perisic Z, et al. The impact of environmental and behavioural cofactors on the development of cervical disorders in HR-HPV-infected women in Serbia. Epidemiol Infect. 2018;146(13):1714-1723.
Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key Molecular Events in Cervical Cancer Development. Medicina (Kaunas). 2019;55(7):384.
Schiffman M, Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med. 2013;369(24):2324-31.
Hanna E, Bachmann G. HPV vaccination with Gardasil: a breakthrough in women's health. Expert Opin Biol Ther. 2006;6(11):1223-7.
European Medicines Agency [Internet]. [cited 2023 Dec 23]. Available from: https://www.ema.europa.eu/en/medicines
Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front Immunol. 2022;12:805695.
Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196-204.
Schiller JT, Muller M. Next generation prophy- lactic human papillomavirus vaccines. Lancet Oncol. 2015;16(5):e217–e225.
Maver PJ, Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018;36(36):5416-23.
Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23(41):1700737.
Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958-66.
Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497-509.
Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, et al. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis. 2018;66(3):339-45.
Izveštaj o sprovedenoj imunizaciji na teritoriji Republike Srbije [Internet]. Batut; 2023 [cited 2024 Jan 15]. Available from: https://www.batut.org.rs/download/izvestaji/2022izvestajOSprovedenoj
Imunizaciji.pdf.
HPPV Vaccine [Internet]. Centers for Disease Control and Prevention [cited 2023 Dec 23]. Available from: https://www.cdc.gov/hpv/parents/vaccine-for-hpv.html.
Gardasil 9 [Internet]. European Medicines Agency [cited 2023 Dec 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9.
Human Papillomavirus (HPV) Vaccine [Internet]. Centers for Disease Control and Prevention [cited 2023 Dec 23]. Available from: https://www.cdc.gov/vaccinesafety/vaccines/hpv-vaccine.html.
Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32 Pt A):4768-73.
Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res. 2019;8:100185.
Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459-66.
Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016;12(1):20-9.
Shapiro GK. HPV Vaccination: An Underused Strategy for the Prevention of Cancer. Curr Oncol. 2022;29(5):3780-92.
Schiller JT. The Biological Rationale for a One Dose HPV Vaccine [Internet]. HPW: The newsletter on HPV [cited 2023 Dec 23]. Available from: https://www.hpvworld.com/articles/the-biological-rationale-for-a-one-dose-hpv-vaccine/.
Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol. 2014;45:58-74.
Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012;10(10):681-92.
Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. World Health Organization [cited 2024 Jan 15]. Available from: https://iris.who.int/bitstream/handle/10665/336583/9789240014107-eng.pdf?sequence=1.
Cervical Cancer Elimination Initiative [Internet]. [cited 2023 Dec 23]. Available from: https://cceirepository.who.int.
Cervical Cancer Elimination Initiative [Internet]. World Health Organization [cited 2023 Dec 23]. Available from: https://www.who.int/initiatives/cervical-cancer-elimination-initiative.
Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. World Health Organization; 2020 Nov 17 [cited 2023 Dec 23]. Available from: https://www.who.int/publications/i/item/9789240014107.
Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer. 2023;33:649–66.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Cervical Cancer Treatment: Patient Version; 2023 Nov 2 [cited 2023 Dec 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65985/
Mayadev JS, Ke G, Mahantshetty U, Pereira MD, Tarnawski R, Toita T. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. Int J Gynecol Cancer. 2022;32(3):436-45.
Cervical Cancer Treatment [Internet]. National Cancer Institute [cited 2023 Dec 23]. Available from: https://www.cancer.gov/types/cervical/treatment.
Yang SL, Chen L, He Y, Zhao H, Wu YM. Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage I-II cervical cancer: a meta-analysis. J Int Med Res. 2020 Aug;48(8):300060520945507.
NCCN [Internet]. Clinical practice guidelines in oncology: cervical cancer. v.1.2022 [cited 2023 Dec 23]. Available from: nccn.org.
Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, et al. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial. JAMA Oncol. 2018;4(4):506-13.
Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. J Clin Oncol. 2023;41:5505-5511.
Oaknin A, Gladieff L, Martinez-Garcia J, Villacampa G, Takekuma M, De Giorgi UFF, et al. Primary results from BEATcc (ENGOT-Cx10/ GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer. ESMO virtual plenary abstracts. 2023;34(12):P1198-1200.
Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagameri A, Ghamande S, et al. InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Ann Oncol. 2023;34:S1276-7.
Markham A. Tisotumab Vedotin: First Approval. Drugs. 2021;81(18):2141-47.
Keam SJ. Cadonilimab: First Approval. Drugs. 2022;82(12):1333-9.
Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020;21(12):1653-60.
Zamarin D, Deng W, Lankes H, Ghamande S, Holman L, Mathews C, et al. Evolution of peripheral and tumor immune parameters as biomarkers of differential sequencing of immune checkpoint blockade and chemoradiotherapy in locally advanced cervical cancer: an NRG Oncology/GOG study. Gynecol Oncol. 2023;176(1S):S6.
Duska LR, Showalter TN, Petroni GR, Bullock T. A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer. J Clin Oncol. 2017;35:TPS5601-TPS5601.
Lorusso D, Xian Y, Hasegawa K, Scambia G, Leiva Galves MH, Ramos Elias P, et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18. Ann Oncol. 2023;34:S1279-80.
McCormack M, Gallardo Rincón D, Eminowicz G, Diez P, Farrelly L, Kent C, et al. A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial. Ann Oncol. 2023;34:S1276.
